Androgen-deprivation therapy plus abiraterone and prednisolone vs combined androgen blockade for high-risk, metastatic, castration-sensitive prostate cancer : A randomized controlled trial

Androgen-deprivation therapy plus abiraterone and prednisolone vs combined androgen blockade for high-risk, metastatic, castration-sensitive prostate cancer : A randomized controlled trial - Androgen-deprivation therapy plus abiraterone and prednisolone vs combined androgen blockade for high-risk, metastatic, castration-sensitive prostate cancer : A randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035933

Enrollment

Registered

2019-02-20

Start date

2019-03-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high-risk, metastatic, castration-sensitive prostate cancer

Interventions

Androgen-deprivation therapy plus abiraterone and prednisolone combined androgen blockade

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: patients are required to have at least two of the three following high-risk factors associated with poor prognosis: a Gleason score of 8 or more, at least three bone metastatic lesions, and the presence of measurable visceral metastasis.

Exclusion criteria

Exclusion criteria: 1. Cases with no prostate biopsy 2. Cases with other cancers

Design outcomes

Primary

Measure	Time frame
time to biochemical recurrence (prostate specific antigen failure)	—

Countries

Japan

Contacts

Public ContactKawamura Norihiko

Osaka General Medical Center Department of Urology

norijilmur@gmail.com06-6692-1201

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026